As the 2020 pandemic became a distant memory and millions of Americans returned back to their old lives, some were left suffering debilitating side effects ...

Gennova has been working on self-amplifying mRNA vaccine. mRNA vaccines use body’s machinery to make antigenic protein rather ...

Bristol Myers Squibb plans to close its viral vector production facility in Libertyville, IL according to a BMS spokesperson ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and ...

The Viral Vector & Plasmid DNA Manufacturing Market Size accounted for USD 5.4 Billion in 2023 and is estimated to achieve a market size of USD 24.6 Billion by 2032 growing at a CAGR of 18.5% from ...

“We are thrilled to partner with Viral Vector Manufacturing Facility to facilitate its transition to commercial-scale manufacturing of high-quality viral vectors. SYSPRO Cloud ERP will act as ...

and user of viral vectors. However, it is far from a unique opinion in the sector. Most CDMOs working in the space recognize the need for better vector production technologies and have been making ...

From rare diseases to common chronic conditions, advances in viral vector-based gene therapies are bringing exciting new clinical possibilities to the table. But current costs per dose land as ...

Welcome to the Moderna first-quarter 2025 conference call. (Operator Instructions) Please be advised, today's conference is being recorded. I would now like to hand the conference over to your ...

From STAT’s Jason Mast: Moderna said this morning in its earnings report it planned to cut costs by around $1.5 billion by 2027, adding $700 million to $1 billion on top of more modest cuts ...